– USA, UT – Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced the election of Dr. Daniel Skovronsky to its Board of Directors, effective immediately, expanding the Board to ten members. Additionally, Dr. Skovronsky was appointed to the Research and Product Innovation Committee of the Board.
“We are honored to welcome Dr. Skovronsky to the Myriad Board,” said Louise Phanstiel, Chair of the Board of Myriad. “Dan brings a wealth of experience and expertise in research and development in multiple areas related to our diagnostic product development, including oncology, neuroscience, and anti-inflammatory diseases. He will be instrumental in providing product development strategic insights in executing our global strategy for molecular diagnostics and precision medicine.”
The Company also announced today that Director, Vice-Chair of the Board, Dr Wally Gilbert will retire from the board at the Annual Meeting of Stockholders in December 2020. Dr. Gilbert, the co-founder of Myriad, has been on the board since March 1992. Dr. Gilbert received a Nobel Prize in Chemistry in 1980 for his development of a rapid DNA sequencing technology.
“I am proud that Myriad has grown to realize its founders’ dream of using tests based on genetic information to identify a patient’s predisposition to disease,” said Dr. Gilbert. “Myriad is dedicated to providing critical, life-changing information to people to help define their individual medical needs. I have enjoyed helping the company grow over the years. I am confident that Myriad’s important work for patients will continue.”
Louise Phanstiel commented, “The Board owes a tremendous debt of gratitude to Wally for all of his countless contributions to the company and to the board over the years. His relentless focus on the pursuit of scientific excellence and compassion for our patients as well as our Myriad team are qualities we all aspire to emulate. The board, the company, and I will greatly miss his wisdom, counsel, and passion. We wish Wally all the best.”
About Dr. Daniel Skovronsky
Dr. Skovronsky serves as CSO and President of Lilly Research Laboratories at Eli Lilly and Company. He previously served as the Founder and CEO of Avid Radiopharmaceuticals, Inc. which used non-invasive imaging to detect the early changes in the brain related to Alzheimer’s disease.
Dr. Skovronsky received his M.D., Ph.D. from the University of Pennsylvania where he also completed sub-specialty training in neuropathology.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.
For more information: https://myriad.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
